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Cystic fibrosis is caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene, which encodes a chloride channel present in many
cells. In cardiomyocytes, we report that multiple exon 1
usage and alternative splicing produces four CFTR
transcripts, with different 5-untranslated regions,
CFTRTRAD-139, CFTR1C/1A, CFTR1C, and CFTR1B.
CFTR transcripts containing the novel upstream exons
(exons 1C, 1B, and 1A) represent more than 90% of
cardiac expressed CFTR mRNA. Regulation of cardiac
CFTR expression, in response to developmental and
pathological stimuli, is exclusively due to the modula-
tion of CFTR1C and CFTR1C/1A expression. Upstream
open reading frames have been identified in the 5-un-
translated regions of all CFTR transcripts that, in con-
junction with adjacent stem-loop structures, modulate
the efficiency of translation initiation at the AUG codon
of the main CFTR coding region in CFTRTRAD-139 and
CFTR1C/1A transcripts. Exon 1A, only present in
CFTR1C/1A transcripts, encodes an AUG codon that is
in-frame with the main CFTR open reading frame, the
efficient translation of which produces a novel CFTR
protein isoform with a curtailed amino terminus. As the
expression of this CFTR transcript parallels the spatial
and temporal distribution of the cAMP-activated whole-
cell current density in normal and diseased hearts, we
suggest that CFTR1C/1A provides the molecular basis
for the cardiac cAMP-activated chloride channel. Our
findings provide further insight into the complex nature
of in vivo CFTR expression, to which multiple mRNA
transcripts, protein isoforms, and post-transcriptional
regulatory mechanisms are now added.
Cystic fibrosis (CF)1 is an autosomal recessive disorder that
causes severe multisystem disease (1). The cause of CF is
mutation of the cystic fibrosis transmembrane conductance
regulator gene (CFTR) (2–4), which encodes a cAMP-activated,
protein kinase A-dependent chloride channel (5, 6) and is a
member of the ABC transporter superfamily of genes (7). CFTR
exhibits spatial and temporal regulation of expression (8–10),
accompanied by different transcription start site usage (11)
and alternative splicing (12, 13). In addition to epithelial tis-
sues, CFTR is expressed in cardiac muscle (14, 15) and neuro-
nal tissues (16, 17), which may contribute to the pathogenesis
of CF.
The expression of CFTR transcripts and cAMP-activated chlo-
ride currents in the heart have been demonstrated for humans
and simians (18), rabbits (19), guinea pigs (20, 21), and cats (22),
but are undetectable in murine (23) and canine hearts (24).
Previous studies have shown that CFTR transcripts expressed in
the heart are alternatively spliced, resulting in the loss of exon 5
(25). We have previously demonstrated that CFTR mRNA is
expressed in an epicardial (higher) to endocardial (lower) gradi-
ent across the left ventricular free wall (LVFW) of the rabbit
heart, coinciding with a 2.5:1 gradient in the cAMP-activated
chloride current density in ventricular myocytes (26). Further-
more, this epicardial to endocardial gradient in CFTR expression
is developmentally regulated, appearing in the first postnatal
week (27), and lost in hypertrophic and failing hearts (28). The
cardiac distributions of CFTR mRNA and functional channels
are consistent with a role in the maintenance of the normal
epicardial to endocardial gradients of ventricular repolarization
and action potential duration in the heart (14, 26). In addition,
the overall reduction and loss of the gradient of CFTR expression
during hypertrophy could contribute to delayed ventricular repo-
larization (29) and loss of the gradient of repolarization in hyper-
trophied hearts (30), both of which are known to be arrhythmo-
genic (31). Indeed, it has been shown that some CF patients
exhibit an increased risk of ventricular arrhythmia (32, 33);
however, it is difficult to distinguish between a primary genetic
cause due to the loss of CFTR expression and secondary effects as
a result of pathological manifestations in the pulmonary system.
In this study, we investigated the regulation of temporal,
regional, and pathological changes in CFTR expression in the
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rabbit heart. We show that the majority of CFTR transcripts
expressed in the heart initiate at unique transcription start
sites and include novel alternative 5-exons that replace the
traditional CFTR exon 1. These alternative 5-exons encode (a)
a series of short upstream open reading frames (uORFs) in the
5-untranslated region (5-UTR), resulting in post-transcrip-
tional regulation of CFTR expression, and (b) a unique trans-
lation initiation codon, in-frame with the main CFTR open
reading frame (ORF), which results in a CFTR polypeptide
with a distinct amino terminus. Modulation in the levels of
these cardiac-specific CFTR transcripts is responsible for the
temporal, spatial, and pathological changes in CFTR expres-
sion observed in the heart. Finally, the distal localization of
these cardiac-specific, alternative 5-exons upstream of the tra-
ditional CFTR exon 1 suggests the presence of a distinct pro-
moter region directing CFTR expression in the heart.
EXPERIMENTAL PROCEDURES
Total RNA Source and Preparation—Triplicate New Zealand White
rabbit tissue samples were collected from heart (embryo day 29, neo-
nate day 7, juvenile week 3, adult year 1; left and right ventricular free
wall, sham-operated control, and aortic-banded hypertrophy) and adult
year 1 duodenum (control). All atrial tissue was removed from each
cardiac sample harvested, except for embryo day 29, where whole
hearts were used. Atrial tissue contributes less than 10% of the tissue
weight to the embryo day 29 samples and will not significantly affect
the comparison of CFTR expression during development. Moderate
cardiac hypertrophy was induced in adult rabbits as previously de-
scribed (34), resulting in an increased heart weight-to-body weight ratio
of 26  2%. Sham-operated animals underwent aortic mobilization, but
were not banded. Adult LVFW samples were dissected into three equal
parts, along both the apical to basal and epicardial to endocardial axes,
and the outer portions located at the apical epicardial, basal epicardial,
apical endocardial, and basal endocardial surfaces were taken for fur-
ther analysis. All procedures were performed in accordance with the
United Kingdom Animals (Scientific Procedures) Act of 1986. Fresh
tissues were homogenized in guanidinium thiocyanate solution (Fluka),
and total RNA was isolated according to Chomczynski and Sacchi (35).
5-Rapid Amplification of cDNA Ends (5-RACE)—CFTR transcrip-
tion start sites were identified by 5-RACE as previously described (11).
Total RNA (2 g) was reverse transcribed using a CFTR exon 6 reverse
primer (Table I). First-strand cDNAs, tailed with dCTP, were subject to
two rounds of hemi-nested PCR using reverse primers to exons 4, 3, or
2 and an anchor primer to the dC tail. Amplicons were sequenced
directly and subcloned into pLITMUS 28 (New England Biolabs).
Northern Blot Analysis—Rabbit CFTR cDNA (courtesy of Professor
Burton Horowitz, University of Nevada School of Medicine, Reno, NV)
was random-primer radiolabeled with [-32P]dCTP (3000 Ci mM, Am-
ersham Biosciences; DECAprime II system, Ambion). Total RNA was
electrophoresed on a 1% (w/v) denaturing agarose gel, transferred to a
positively charged nylon membrane (GeneScreen Plus, PerkinElmer
Life Sciences), incubated with labeled probe, and then washed as pre-
viously described (13). Autoradiography was with Hyperfilm MP x-ray
film (Amersham Biosciences) for 5 days.
TaqMan Quantitative PCR (qPCR)—Relative CFTR expression was
quantified using cDNA primed with random hexamer (500 ng) with
transcript-specific forward primers (exons 1C, 1B, 1A, 1, 4, and 5),
reverse primers and probes (exons 2 and 6), all designed to cross at least
one exon-exon boundary (Table I). The 5-reporter and 3-quencher dyes
used for CFTR probes were 6-carboxyfluorescein and 6-carboxytetram-
ethylrhodamine, respectively, whereas the 18 S rRNA probe used the
VIC reporter dye (Applied Biosystems). Each qPCR reaction consisted
of 1 TaqMan Universal PCR Master Mix (Applied Biosystems), for-
ward and reverse primers (250 nM), probe (50 nM), and cDNA template
(100 ng). Triplicate experimental CFTR and endogenous 18 S rRNA
reactions were performed using three independent cDNA samples from
different animals. Reporter dye fluorescence was detected using an
Applied Biosystems Prism 7700 Sequence Detector, and data were
analyzed using Sequence Detector software version 1.6.3 (Applied Bio-
systems). Quantification of CFTR gene expression, relative to 18 S
rRNA, was performed using the comparative threshold cycle method
according to instructions from the manufacturer (Applied Biosystems).
Construction of CFTR-Enhanced Green Fluorescent Protein (eGFP)
Fusion Constructs and Cell Culture—CFTR cDNA fragments contain-
ing each alternative or traditional exon 1 sequence plus exon 2 were
ligated to the eGFP cDNA (Clontech) and the entire fragment subcloned
into the pIRESneo mammalian expression vector (Clontech). Chinese
hamster ovary (CHO) cells (ATCC, CRL-9096; courtesy of Dr. Yu Lu,
University of Cambridge, Cambridge, United Kingdom) were grown in
Iscove’s modified Dulbecco’s medium, 10% (v/v) fetal bovine serum, 4
mM L-glutamine, 18 mM sodium bicarbonate, 0.1 mM hypoxanthine, and
16 M thymidine (Invitrogen). Triplicate wells of 60% confluent CHO
cells were transiently co-transfected with 1 g each of CFTR-eGFP and
control enhanced blue fluorescent protein (eBFP) constructs, using Li-
pofectAMINE according to the instructions from the manufacturer (In-
vitrogen). After 72 h of incubation, cells were trypsinized and trans-
ferred to a Thermo-Fast 96 black PCR plate (Abgene). Enhanced GFP
and eBFP fluorescence was measured using a SPECTRAmax GEMI-
NI-XS spectrofluorometer (36, 37). Prior calibration experiments deter-
mined the following optimal parameters: for eGFP, ex  472 nm, em 
512 nm, and cutoff  495 nm; and for eBFP, ex  378 nm, em  445
nm, and cutoff  420 nm. To correct for differences in transfection
efficiency, eGFP fluorescence values were normalized to eBFP signal.
Background fluorescence (untransfected cells) was subtracted.
Bioinformatic and Statistical Analyses—Messenger RNA secondary
structures were predicted using MFold version 3.1 (38, 39). CFTR
amino-terminal hydropathy plots were generated using the Kyte and
Doolittle algorithm (40). Protein secondary structures were predicted
by PSIPRED version 2.4 (41). The charge distribution for the putative
CFTR amino-terminal helix was predicted by helical wheel analyses
using MacPlasmap Pro version 3.01. Statistical comparisons were made
using Student’s t tests (unpaired, two-tailed), and a p value of less than
0.05 was taken to indicate that a change in transcript level was of
statistical significance.
RESULTS
CFTR Transcripts Expressed in Rabbit Heart Include Multi-
ple Alternative 5-Exons—The major in vivo transcription start
sites of CFTR transcripts expressed in the heart were identified
by 5-RACE. Typical examples of 5-RACE products obtained
from adult LVFW and duodenal (control) tissues are shown in
Fig. 1A. Sequencing of 5-RACE amplicons revealed extensive
TABLE I
Oligonucleotide and probe sequences used for 5-RACE PCR and TaqMan qPCR
Primer Sequence Description
Anchor primer/F 5-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3 Anneals to poly dC-tail
RC2/R 5-TTTGGTATATGTCTGACAATTCCAGGCGCT-3 5-RACE rabbit CFTR exon 2
RC3/R 5-ACACCTCCGAAGGGCATTATTGAGCTTAGG-3 5-RACE rabbit CFTR exon 3
RC4/R 5-ACAAAGAGTAAGCACAGACCTATGCCCAGG-3 5-RACE rabbit CFTR exon 4
RC6/R 5-CCAGCTCTCTGATCCCTGTACTTCATCATC-3 5-RACE rabbit CFTR exon 6
Exon 1C/F 5-AACACGCTGTTATTCCTCACCTG-3 TaqMan qPCR CFTR exon 1C
Exon 1B/F 5-GCTCTAGTGAAGATGGTCTACTTGATGA-3 TaqMan qPCR CFTR exon 1B
Exon 1A/F 5-CATCAGAGTTGCACGAATCACAT-3 TaqMan qPCR CFTR exon 1A
Traditional exon 1/F 5-GAGAGACCATGCAGAAGTCGC-3 TaqMan qPCR CFTR traditional exon 1
Exon 2/R 5-CTGCAGAATCAGCAGAAGGGA-3 TaqMan qPCR CFTR exon 2
Exon 4/F 5-GCAGATGAGAATAGCCATGTTCAG-3 TaqMan qPCR CFTR exon 4
Exon 5/F 5-CTCCTTTCCAACAACCTGAACAA-3 TaqMan qPCR CFTR exon 5
Exon 6/R 5-GAAAGCAAGGCCGCAGAA-3 TaqMan qPCR CFTR exon 6
Exon 2/F 5-CTGGACTAGACCGATTTTGAGAAAAGGATACAGACA-3 TaqMan qPCR CFTRexon 2 probe
Exon 6/F 5-ACCTCTGCAAGTGACTCTGCTGATGGG-3 TaqMan qPCR CFTRexon 6 probe
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variation in transcription start site and exon 1 usage in differ-
ent tissues and at different developmental stages.
In adult duodenal tissues, a single transcription start site
was identified 74 bp upstream of the first base of the transla-
tion initiation codon in traditional rabbit CFTR exon 1
(CFTRTRAD-74). The nucleotide sequence was identical to the
published rabbit CFTR cDNA and promoter sequences (Gen-
BankTM accession nos. OC40227 and X95931). Similarly, CFTR
transcripts expressed in embryonic cardiac ventricle initiated
in traditional exon 1, but included some 65 additional nucleo-
tides and initiated transcription at position 139 bp
(CFTRTRAD-139) (Fig. 1B; GenBank
TM accession no. AY256889).
In adult and neonatal cardiac ventricle, as well as hypertrophic
heart, multiple in vivo transcription start sites were identified
(Fig. 1, A and B). Collectively, sequence analysis revealed three
new alternative 5-CFTR exons, designated exon 1C, exon
1B, and exon 1A, respectively (GenBankTM accession nos.
AY256886–AY256888). Exon 1C and exon 1B are spliced
directly to exon 2, with exon1A subject to alternative splicing
between exons 1C and 2 (CFTR1C, CFTR1B, and CFTR1C/
1A transcripts). All splice donor and acceptor sequences satis-
fied the GT-AG rule (42). Fig. 1B shows the genomic structure
and alternative splicing of CFTR transcripts expressed in the
heart. In all cases, amplification reactions from control un-
tailed cDNA were negative. Identical CFTR transcription start
sites were mapped using three independent samples for all
tissue types, confirming the precise location of each identified
transcription start site and ensuring artifacts caused by partial
mRNA degradation were avoided.
Transcripts that included exon 1A contain an AUG codon
FIG. 1. Differential transcription start site and alternative exon 1 usage in rabbit tissues. A, representative 5-RACE amplicons from
adult rabbit (i) heart and (ii) duodenal cDNA samples. Sample order for both gels: lane 1, marker; lane 2, anchor primer and exon 3 primer amplicon
(3); lane 3, negative control reaction (cDNA not tailed with terminal deoxynucleotidyltransferase (No TdT)). Lane 4, anchor primer and exon 2
primer amplicon (2). Lane 5, no TdT negative control. B, a schematic representation of the rabbit CFTR genomic locus showing alternative
splicing (black lines) and uORFs. Transcription start sites (black vertical line) are indicated: H, heart; D, duodenum; with subscript designations
for adult (A), embryo (E), adult hypertrophic heart (H); and neonate (N). Vertical arrows indicate an AUG codon in-frame with exon 2. \\ represents
intron 1A (6 kb in the human genome). // represents intron 1 (24.5 kb in the human genome). Putative uORFs are shown as light gray boxes
beneath CFTR exons 1C to 2, where the 5 end represents an AUG codon, the 3 end represents a termination codon, and the intervening vertical
lines represent internal AUG codons. Junctions between uORFs that cross exon-exon boundaries are shown with light gray lines. C, summary table
showing the degree, the length, and the relative position of identity between each rabbit CFTR alternative exon 1 sequence and the human BAC
sequence (GenBankTM accession no. AC000111). The relative position of identity is numbered with respect to the human CFTR translation
initiation codon.
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in-frame with the main CFTR ORF. Translation initiation from
this AUG codon would result in CFTR protein with a novel
amino-terminal region. Exons1B and1C did not contain an
AUG codon in-frame with the main CFTR ORF. However,
many upstream AUGs (uAUGs) were identified in the 5-UTR
of CFTR transcripts including exons 1C, 1B, or 1A, and a
single uAUG codon was identified in the 5-UTR of CFTRTRAD-
139. These uAUGs defined the start of several uORFs, which
were followed by translation termination codons and thus en-
coded short peptides. The presence of short uORFs in the
5-UTRs of eukaryotic mRNA transcripts is indicative of post-
transcriptional and translational regulation of gene expression
(43). Data base comparisons of each putative short polypeptide
sequence revealed no homology to known protein sequences.
Genomic DNA Structure and Transcriptional Control of
CFTR Expression in the Heart—Rabbit genomic DNA (gDNA)
spanning CFTR exon 1C to exon 1A, was amplified by long
range PCR and the sequence compared with the human and
mouse gDNA sequences (GenBankTM accession nos. AC000111
and AF162137; see Fig. 1C and supplemental data (available in
the on-line version of this article) showing dot matrix compar-
isons of rabbit, mouse, and human sequences). We also com-
pared CFTR traditional exon 1 and flanking sequences across
the three species. In both exonic and intronic gDNA regions,
human and rabbit sequences showed a high level of identity for
both the CFTR exon 1C to 1A region and traditional exon 1
(Fig. 1C). However, only CFTR traditional exon 1 sequences
showed any similarity between the mouse and the other spe-
cies. The human homologues of rabbit CFTR exons1C to1A
spanned a region located 6–9 kb upstream of the traditional
human CFTR exon 1. Further, the short uORFs and the rabbit
CFTR exon 1A AUG codon, that is in-frame with the main
CFTR ORF, are conserved in the human genome. The presence
of homologues of the rabbit alternative exon 1 sequences in the
human genome, but not the mouse, is consistent with expres-
sion of CFTR in the hearts of many species, including the
rabbit (Fig. 3A) (15) and human (18), but not in the mouse
(tested by RNA in situ hybridization and two rounds of reverse
transcription-polymerase chain reaction; data not shown). Only
2 kb of genomic DNA sequence upstream of rabbit CFTR tra-
ditional exon 1 is available, and the alternative CFTR exons
1A to 1C lie beyond that. Long range PCR between CFTR
traditional exon 1 and exons 1A to 1C, using rabbit gDNA
template, was unsuccessful. Therefore, the promoter region
controlling the expression of CFTR exons 1C, 1B, and 1A
is likely to be distally located and cardiac-specific.
Greater than 90% of CFTR Transcripts Expressed in the
Heart Initiate at Exon 1C or 1B—Total CFTR mRNA ex-
pression in rabbit adult LVFW was similar to the level of CFTR
expression detected in duodenal epithelium. A 6.5 kb CFTR
transcript was detected in both tissues (Fig. 2A), which is
consistent with the known CFTR transcript size (3). Past stud-
ies have also shown alternative splicing of exon 5 (25), and
changes in total CFTR expression during heart development
(27) and in cardiac hypertrophy (28). To investigate the biolog-
ical relevance of the multiple alternative CFTR transcripts, we
measured the relative expression level of individual CFTR
transcripts in rabbit heart tissue from embryo day 29, neonate
day 7, juvenile week 3, and normal adult left ventricle (LV) and
right ventricle (RV).
We used TaqMan quantitative PCR (qPCR) to quantify each
distinct CFTR transcript: CFTR1C, CFTR1B, CFTR1C/1A,
CFTRTRAD-139, CFTREXON5, and CFTREXON5. In all cases,
amplicons were less than 150 bp, the standard curve plots
showed a very high correlation coefficient (R2 0.99, p 0.01),
and amplification efficiencies were close to 100%. The expres-
sion levels of each CFTR transcript were measured in arbitrary
relative expression units and normalized to 18 S rRNA. We
compared CFTR expression in whole heart (atria and ventri-
cles) from embryo day 29, and ventricular tissues from neonate
day 7, juvenile week 3, and normal adult year 1 LV and RV.
Atrial tissue contributes less than 10% of the tissue weight to
the embryo day 29 samples and will not significantly affect the
comparison of CFTR expression during development.
The predominantly expressed CFTR transcript in early rab-
bit cardiac development was CFTR1B, with lower levels of the
CFTR1C and CFTR1C/1A transcripts (Fig. 2B). As develop-
ment proceeds the expression of CFTR1B transcripts de-
creased (p  0.05), whereas expression of both CFTR1C and
CFTR1C/1A transcripts increased and became the predomi-
nant CFTR transcripts in the adult rabbit heart (p  0.05 and
p  0.05, respectively). In contrast, the expression of
CFTRTRAD-139 transcripts was low and static. In adult cardiac
tissue, greater than 90% of total CFTR mRNA transcripts
include the novel alternative exons (exon 1C, exon 1B, and
exon1C/1A) described here. This contrasts with duodenum,
where more than 95% of CFTR transcripts initiate from tradi-
tional CFTR exon 1.
FIG. 2. Rabbit CFTR expression in the developing heart. A, Northern blot analysis of CFTR mRNA in rabbit adult heart ventricle (H) and
duodenum (D) (top panel). Corresponding ethidium bromide-stained agarose gel with 30 g of total RNA/lane (bottom panel). B and C, quantitative
PCR analysis of CFTR expression during cardiac development. B, the relative expression levels of each alternative CFTR transcript, CFTR1C,
CFTR1B, CFTR1C/1A, and traditional CFTRTRAD-139, were measured using forward primers specific to exon 1 of each transcript and a common
reverse primer and TaqMan probe to CFTR exon 2. C, the relative expression levels of the exon 5 alternatively spliced CFTR transcripts,
CFTREXON5 (black) and CFTREXON5 (white), were measured using forward primers in exons 4 and 5 and a common reverse primer and TaqMan
probe to CFTR exon 6. Reaction conditions were such that the exon 4 primer only amplified the CFTR exon 5 minus transcript (52). All expression
levels were measured relative to 18 S rRNA. In all cases error bars equal one standard deviation. Hrt, heart; Emb, embryo day 29; Neo, neonate
day 7; Juv, juvenile week 3; V, both left and right ventricles; Ad, adult; LV, left ventricle; RV, right ventricle.
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Analysis of CFTR exon 5 alternative splicing showed equal
levels of exon 5 and exon 5- CFTR transcripts at embryonic
and neonatal stages (Fig. 3C). In hearts from juvenile and adult
animals, there were differential increases in expression of both
CFTREXON5, and CFTREXON5 isoforms. This resulted in
CFTREXON5 transcripts being 3-fold more abundant than
CFTREXON5 transcripts in the LVFW of adult hearts (p 
0.05). This also contrasts with CFTR expression in adult duo-
denum, where over 90% of CFTR transcripts include exon 5.
The Expression of CFTR Transcripts Initiating at Exon 1C
Is Primarily Responsible for the Epicardial to Endocardial
Gradient across the LVFW—Epicardial (higher) to endocardial
(lower) gradients across the rabbit LVFW have been shown for
both cAMP-activated chloride currents and CFTR expression
(26). Quantitative analysis of the differential distribution of
each CFTR transcript in the adult LVFW shows that CFTR1C
and CFTR1C/1A transcripts, as well as alternatively spliced
CFTREXON5 transcripts, are responsible for the epicardial to
endocardial gradient of CFTR expression and function in the
left ventricle (Fig. 3, A (i and iii) and B, p  0.05 in all cases).
In contrast, there were no substantial differences in epicardial
versus endocardial expression of CFTR1B, CFTRTRAD-139, or
CFTREXON5 transcripts (Fig. 3, A (ii and iv) and B).
This work has also identified a second, perpendicular gradient
in CFTR expression along the apical to basal axis of the left
ventricle (Fig. 3, A and B). All three cardiac-specific CFTR tran-
scripts (CFTR1C, CFTR1B, and CFTR1C/1A) and both exon 5
alternatively spliced forms contribute to the apical to basal gra-
dient (p  0.05 in all cases). Collectively, these data show that
CFTR expression is distributed in a radial pattern across the
LVFW: highest at the apical epicardial surface and decreasing
radially to the lowest point at the basal endocardial surface.
Cardiac Hypertrophy Causes the Loss of the Epicardial to
Endocardial Gradient, but Does Not Alter the Apical to Basal
Gradient of CFTR Expression—Cardiac ventricular hypertro-
phy is associated with a loss of repolarizing ion currents, in-
cluding CFTR (28), and prolongation of the ventricular action
potential duration (44). Here we show that the loss of the
epicardial to endocardial CFTR expression gradient, in hyper-
trophic hearts, is caused by the preferential down-regulation of
CFTR1C and CFTR1C/1A transcripts (Fig. 3A; p 0.05 in all
cases), whereas CFTR1B and CFTRTRAD-139 transcripts were
unaffected (Fig. 3A (ii and iv)). Although cardiac hypertrophy
resulted in the loss of the epicardial to endocardial CFTR
expression gradient, the apical to basal gradient was
unaffected.
Cardiac hypertrophy also differentially affected the expres-
sion of exon 5 alternatively spliced CFTR transcripts (Fig. 3B).
The establishment of cardiac hypertrophy leads to a loss of the
epicardial to endocardial gradient of CFTREXON5 transcripts,
whereas CFTREXON5 transcripts remain evenly distributed
across the epicardial to endocardial axis. Further, both exon 5
alternatively spliced transcripts contribute to the apical to
basal gradient in CFTR expression. The overall increase in
CFTR expression during development reflects a preferential
accumulation of CFTR1C and CFTR1C/1A transcripts and a
shift in exon 5 alternative splicing, such that CFTREXON5
transcripts predominate. This process is reversed in cardiac
hypertrophy with preferential loss of CFTR1C, CFTR1C/1A,
and CFTREXON5 transcripts.
The Translation Initiation Codon in Exon 1A Supports
CFTR Protein Production—In the absence of traditional CFTR
exon 1, Carroll and co-workers (45) have provided evidence for
translation initiation from downstream AUG codons, for exam-
ple those present in exons 3 and 4. Of the CFTR transcripts
expressed in the heart, only CFTRTRAD-139 and CFTR1C/1A
transcripts contain an AUG codon upstream of exon 2 and
in-frame with the main CFTR ORF. Both translation initiation
codons, in exon 1A and traditional exon 1, equally match an
optimal Kozak consensus sequence. Fig. 4A shows a compari-
son of the sequences surrounding each AUG codon and the
Kozak consensus sequence (46). AUG codons present in exons 3
and 4 all showed significantly lower identity to the Kozak
consensus sequence, suggesting translation initiation at AUG
codons in exons 3 and 4 would be less efficient than at AUG
codons in either exon 1A or traditional exon 1. Exon 3 and 4
AUG codons are the first AUG codons in-frame with the main
CFTR ORF present in CFTR1C and CFTR1B transcripts.
To investigate the potential for translation of each alterna-
tive CFTR transcript identified in this study, fusion constructs
were produced that linked the amino-terminal alternative exon
1 sequences, plus exon 2, to the cDNA encoding an enhanced
Aequorea victoria eGFP, each under the control of a cytomeg-
alovirus promoter. An internal ribosomal entry site element,
located downstream of the eGFP translation termination
codon, artificially stabilized the expressed CFTR-eGFP tran-
scripts, thus limiting any undesired variation in translation
efficiency resulting from differences in mRNA stability. Inde-
pendent constructs were transiently transfected in CHO cells,
and GFP fluorescence, indicating protein expression, was
measured with a spectrofluorometer.
This experiment showed that efficient translation initiation
does occur from the AUG codon identified in CFTR exon 1A,
with an identical level of expressed protein produced by trans-
lation from the AUG codon in traditional CFTR exon 1 (Fig.
4B). There was no significant protein production from exon
1C and exon 1B fusion constructs. Protein expression from
the AUG codons in either exon 1A or traditional exon 1 were
8-fold lower than eGFP alone (p  0.01), suggesting that there
may be elements within the 5-UTRs of either CFTR1C/1A or
CFTRTRAD-139 transcripts that may modulate the efficiency of
translation initiation.
Upstream ORFs and 5-UTR Secondary Structure Post-tran-
scriptionally Modulate CFTR Expression—The presence of
uAUG codons, distinct from the main ORF initiating methio-
nine, in the 5-UTR of most eukaryotic genes is unusual (47,
48). Inspection of the 5-UTRs of the CFTR1C, CFTR1B,
CFTR1C/1A, and CFTRTRAD-139 transcripts identified 16 pu-
tative translation initiation codons associated with uORFs. In
the CFTR1C/1A transcript, we identified five uORFs in the
5-UTR, whereas CFTRTRAD-139 encoded one uORF in the 5-
UTR. McCarthy and co-workers (43) have demonstrated that
uORFs and mRNA secondary structure, such as stem-loops,
can act alone or in combination to regulate translation initia-
tion efficiency at downstream AUG codons.
Although both the CFTRTRAD-139/eGFP and the CFTR1C/
1A/eGFP constructs supported translation, the efficiency of
translation was reduced compared with eGFP alone. With
uORFs and adjacent stem-loop secondary structures in both
these CFTR 5-UTRs, we shortened the 5-UTRs to remove or
reduce the number of uORFs and measured translation from
the AUG of the main CFTR ORF. The CFTR1C/1A/eGFP
construct was truncated to CFTR1A/eGFP, reducing the num-
ber of uORFs from 5 to 3. Also, the 5-UTR of the CFTRTRAD-
139/eGFP construct was truncated by 65 nucleotides, removing
the uORF and producing a 5-UTR typical of CFTR transcripts
expressed in duodenum (CFTRTRAD-74/eGFP).
Reduction in the number of uORFs located upstream of the
in-frame AUG present in exon 1A caused a statistically sig-
nificant (p  0.05, Student’s t test) 1.5-fold increase in protein
production (Fig. 5A). However, the continuing presence of three
uORFs is a likely reason for the still relatively low level of
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FIG. 3. The effect of hypertrophy on rabbit CFTR expression across the LVFW. This figure shows a comparison of CFTR expression in
four distinct regions of the LVFW (epicardial apex, epicardial base, endocardial apex, and endocardial base) from animals with surgically induced
left ventricular hypertrophy and in sham-operated animals. A, the relative expression levels of each alternative CFTR transcript, CFTR1C (i),
CFTR1B (ii), and CFTR1C/1A (iii), and traditional (iv) CFTRTRAD-139 transcripts, were measured using forward primers specific to exon 1 of each
transcript and a common reverse primer and TaqMan probe to CFTR exon 2. B, the relative expression levels of the exon 5 alternatively spliced
CFTR transcripts, CFTREXON5 (black) and CFTREXON5 (white), were measured using forward primers in exons 4 and 5 and a common reverse
primer and TaqMan probe to CFTR exon 6. Reaction conditions were such that the exon 4 primer only amplified the CFTR exon 5 minus transcript
(52). All expression levels were measured relative to 18 S rRNA. In all cases error bars equal one standard deviation. S, sham-operated control
heart tissue; H, hypertrophic heart tissue; Epi, epicardium; Endo, endocardium.
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protein production. The removal of the only uORF in the 5-
UTR of traditional exon 1 resulted in a 3-fold increase in
translation initiation at the AUG of the main CFTR ORF (p 
0.01), but this was still lower than that observed for control
eGFP transfections.
The involvement of secondary structure within the 5-UTR of
CFTR traditional exon 1 was investigated as a possible expla-
nation for the still reduced translation efficiency of the
CFTRTRAD-74/eGFP construct, even in the absence of the uORF.
A mRNA secondary structure prediction program (MFold) was
used to analyze the 5-UTR sequences for traditional exon 1, up
to positions equivalent to 139 bp, from human (GenBankTM
accession no. AC000111), monkey (GenBankTM accession no.
X95930), and rabbit (GenBankTM accession no. X95931). A
conserved uORF was identified in the 5-UTR of traditional
CFTR exon 1 of all three species (Fig. 5B). Computational
prediction of mRNA secondary structure formation identified
classic stem-loop structures localized between the uORF termi-
nation codon and the main ORF start codon. In all species, the
calculated stabilities (	G values) of the stem-loop secondary
structures were in the range of 20 to 30 kcal mol1 (Fig.
5C). Messenger RNA stem-loop structures localized to the 5-
UTR, with similar calculated stabilities, have been shown to
independently reduce translation initiation at a downstream
AUG codon (49–51), but have a stronger inhibitory effect when
localized immediately downstream of an uORF (43). Also, small
differences in the sequence immediately surrounding the AUG
codon, compared with the Kozak consensus, may contribute to
the efficiency of translation.
Translation of CFTR1C/1A mRNA Results in CFTR Pro-
tein with a Unique Amino Terminus—As CFTR exon 1A
splices directly to exon 2, the 17 amino acids encoded by tradi-
tional exon 1 are omitted during translation of CFTR1C/1A
transcripts and 2 other amino acids, encoded by exon 1A,
constitute the new CFTR amino terminus (Fig. 6A). The effi-
ciency of translation of both the CFTRTRAD-139 and CFTR1C/
1A transcripts is indistinguishable (Fig. 4B). As CFTR1C/1A
transcripts are 
6-fold more abundant in adult heart, than
CFTRTRAD-139 transcripts, it is likely that the majority of CFTR
protein expressed in the heart is the curtailed amino terminus
isoform reported here (CFTR1C/1A protein). We have used
computational protein secondary structure and hydropathy
analysis to predict possible differential functional roles of
CFTR1C/1A protein.
Hydropathy analyses over the first 150 amino acids of both
full-length and truncated CFTR isoforms were performed using
the Kyte and Doolittle algorithm (40). The full-length CFTR
amino terminus is predominantly hydrophilic, which is consist-
FIG. 4. Efficiency of translation of
each CFTR transcript expressed in
rabbit heart. A, comparison of putative
translation start codons in exons 1A, 1,
3, and 4 to the Kozak consensus sequence.
Important nucleotides surrounding the
translation initiation codon (bold) at posi-
tions 3 and 4 (boxed) and 5 and 6
(underlined) are indicated. Percentage
homology over positions 9 to 4 (no
brackets) and 9 to 6 (brackets). B, pro-
tein expression from CFTR-eGFP fusion
constructs bearing traditional and alter-
native exon 1 sequences joined to CFTR
exon 2 and eGFP ORF (minus ATG). Pos-
itive control: eGFP (ATG), control eGFP
with translation initiation codon intact.
Negative control: eGFP (ATG–), control
eGFP with translation initiation codon re-
moved. CHO blank, untransfected cells. #
indicates a statistically significant (p 
0.01) difference in protein expression from
transfected cells versus untransfected cells
(CHO blank). Variation in transfection ef-
ficiency was normalized by co-transfection
with a control plasmid expressing blue
fluorescent protein (Clontech).
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ent with previous work (3) and a predicted cytoplasmic local-
ization. However, we report here the identification of a partic-
ularly hydrophobic region, corresponding to amino acids 11–26
of the amino-terminal end and encoded across the exon 1/exon
2 boundary. This amino-terminal hydrophobic region is com-
pletely absent in the curtailed CFTR1C/1A isoform (first de-
scribed by Davies (Ref. 52); Fig. 6B). In contrast, the CFTR
amino acid region involved in binding to syntaxin 1A (53, 54)
was found to be entirely hydrophilic in nature (Fig. 6B, shaded
zone), encoded by exons 2 and 3, and so still present in the
amino-terminal truncated CFTR1C/1A isoform.
CFTR amino-terminal secondary structure was predicted by
PSIPRED. Coinciding with the amino-terminal hydrophobic
region described above (amino acids 11–26) is a putative helical
structure (predicted with a high level of confidence) that spans
the boundary between traditional exon 1 and exon 2 (Fig. 6C).
Helical wheel analysis of this putative, hydrophobic helix pre-
dicts clustering of three positively charged residues (Fig. 6D).
The removal of the amino-terminal half of this putative helix,
as would be the case in the CFTR1C/1A isoform, is accompa-
nied by a marked reduction in the confidence of prediction of
the remainder of the helix. Both secondary structure and hel-
ical wheel predictions were used by Naren and co-workers (54)
in the identification of a helix that has been confirmed to
interact with syntaxin 1A and regulate CFTR channel activity.
DISCUSSION
The distribution and control of CFTR gene expression is
tightly regulated by temporal, spatial, and tissue-specific
mechanisms (8–10). Multiple in vivo transcription start sites
have been localized within 2 kb of the AUG translation initia-
tion codon in traditional CFTR exon 1 (3, 11, 55). This is the
first study showing differential CFTR in vivo transcription
start site usage in the heart that is regulated by temporal,
spatial, and pathophysiological stimuli. CFTR transcripts ex-
pressed in the heart initiate at three distinct exon 1 sequences
(exon1C, exon1B, and traditional exon 1 initiating at139
bp), each of which splice directly to exon 2, with exon 1A
FIG. 5. Post-transcriptional regula-
tion of CFTR expression by uORFs
and stem-loop secondary structures.
A, protein expression from CHO cells
transfected with CFTR-eGFP fusion con-
structs, which correspond to CFTR 5-
UTRs that varied in the number of uORFs
present: Exon 1C/1A, CFTR1C/1A
5-UTR with 5 uORFs; Exon 1A only,
CFTR exon-1A 5-UTR with 3 uORFs;
Trad Exon 1 (139), CFTRTRAD-139
5-UTR with one uORF and stable stem-
loop; Trad Exon 1 (74), CFTRTRAD-74 5-
UTR with stable stem-loop only. Vertical
arrows indicate an AUG codon in-frame
with the main CFTR ORF. Small gray
boxes indicate uORFs. A statistically sig-
nificant difference in protein expression
(p 0.05 and p 0.01) is indicated by the
‡ and # symbols, respectively. Variation
in transfection efficiency was normalized
by co-transfection with a control plasmid
expressing blue fluorescent protein (Clon-
tech). B, phylogenetic comparison of the
human, monkey, and rabbit sequences
surrounding CFTR traditional exon 1.
uORFs (shaded gray) and the main ORF
(black) are highlighted. * represents a ho-
mologous nucleotide and  indicates an
omitted nucleotide. C, cross-species com-
parison of predicted stem-loops located
between the uORFs and the main CFTR
ORF (dotted lines). The 	G value for each
prediction is indicated in units of kcal
mol1.
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alternatively spliced between exon 1C and exon 2. In the
heart, the only previously identified alternative splicing of
CFTR transcripts involved the differential exclusion of exon 5
(12). Exons 1C to 1A are themselves distributed over 2.5 kb
of the rabbit genome and are located distal to the traditional
CFTR exon 1.
Comparative phylogenetic analysis identified human homo-
logues of both the rabbit exon1C to1A and traditional exon
1 CFTR regions, localized 10 kb upstream of human CFTR and
at traditional exon 1, respectively. However, comparison with
murine gDNA only revealed homology to traditional CFTR
exon 1. These findings are consistent with species-specific,
molecular, and functional distributions of CFTR expression in
the heart, identified in humans (18) and rabbits (15, 25) but not
in mice (23). Collectively, these findings suggest that CFTR
transcription from exons 1C to 1A is cardiac-specific and
controlled by a distinct, and previously unidentified, promoter.
Additionally, this work provides support for the development of
a rabbit model of cystic fibrosis, to allow investigation of some
pathophysiological features of human CF disease that are not
present in murine models, such as cardiac involvement in CF
(56).
Spatial, developmental, and pathophysiological signals reg-
ulate CFTR expression in the heart, with the development of a
left ventricular epicardial to endocardial gradient during the
late fetal and neonatal periods, and loss of this gradient follow-
ing hypertrophic stimuli (26–28). We have also identified an
apical (higher) to basal (lower) gradient in CFTR expression
that is unaffected by hypertrophy. This defines a radial pattern
of CFTR expression across the left ventricle, correlating well
with the spread of repolarization throughout the left ventricle.
These findings further support the view that the cAMP-stimu-
lated chloride current, encoded by CFTR, contributes to ven-
tricular repolarization and differential action potential dura-
tion throughout the heart. The expression of multiple CFTR
mRNA transcripts in the heart raises questions of differential
regulation of specific transcripts by various signals.
During cardiac development there is a preferential accumu-
lation of CFTR1C, CFTR1C/1A, and CFTREXON5 tran-
scripts. Concomitantly, there is a preferential loss of CFTR1B
transcripts. Additionally, the epicardial to endocardial gradi-
ent is primarily the result of CFTR1C, CFTR1C/1A, and
CFTREXON5 transcripts, whereas all cardiac-specific CFTR
transcripts contribute to the apical to basal ventricular CFTR
gradient. In contrast, CFTR transcripts initiated at traditional
exon 1 are present at very low, static levels (less than 10%).
Analysis of left ventricular CFTR gradients in the hypertrophic
heart demonstrated a loss of the epicardial to endocardial gra-
dient but not the apical to basal gradient, culminating in an
overall decrease in the radial gradient of ventricular CFTR
expression. Again, individual CFTR transcripts were differ-
entially regulated, with a preferential loss of CFTR1C,
CFTR1C/1A, and CFTREXON5 transcripts, but no change in
CFTR1B and CFTRTRAD-139 expression. The overall increase
in CFTR expression during heart development, and loss in
cardiac hypertrophy is consistent with the “re-expression of
fetal gene program hypothesis” to explain global gene expres-
sion changes in cardiac hypertrophy (57, 58). However, our
findings extend that hypothesis to include differential effects
on individual CFTR transcripts. This demonstration of the
FIG. 6. Characterization of CFTR protein isoforms encoded by CFTR1C/1A and CFTRTRAD-139 transcripts expressed in rabbit
heart. A, comparison of CFTR amino-terminal polypeptide sequences encoded by CFTR1C/1A and CFTRTRAD-139 transcripts. The polypeptide
sequence is identical for both CFTR ORFs downstream of the exon 1 to exon 2 boundary (vertical dotted line). B, hydropathy plot analysis of the
first 150 residues for (i) CFTRTRAD and (ii) CFTR1C/1A polypeptides. The first two transmembrane domains (horizontal bar) of the first
membrane-spanning region are shown (dotted). Also, the location of the putative helix involved in the CFTR/syntaxin 1A interaction is indicated
(dark gray shaded region) (54). The hydrophobic region in CFTRTRAD (black) is highlighted. Open arrows denote the translation initiation codons
identified in CFTRTRAD and CFTR-1C/-1A. C, comparison of protein secondary structure predictions for full-length and truncated CFTR amino
termini. Regions of the CFTR protein are shaded to indicate: the predicted helical structures encoded within exon1A and traditional exon 1 (light
gray); a conserved proline residue (dark gray, boxed); a putative helix involved in the CFTR/syntaxin 1A interaction (dark gray) and transmem-
brane domains (white, boxed). Protein secondary structure (C, coil; H, helix) and confidence of predictions (0, low; 9, high) are indicated. D, helical
wheel plot of the amino-terminal region containing the putative helix identified in the CFTRTRAD protein. The cluster of positively charged residues
present on one surface of the helix is indicated (gray circle).
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differential regulation of individual CFTR transcripts suggests
further complexity in the regulation of CFTR expression, with
mechanisms that allow transcript-specific interpretation of
spatial, temporal, and pathologic signals.
We have identified CFTR regulatory mechanisms that in-
volve both alternative splicing, and differential transcription
start site and exon 1 usage. An important consequence of
differential exon 1 usage is the generation of four CFTR tran-
scripts with distinct 5-UTRs, all of which encode one or more
uORFs. There is increasing evidence that post-transcriptional
regulation of gene expression, through modulation of mRNA
stability and translation initiation, is achieved through 5-UTR
encoded elements, such as uORFs and stem-loop secondary
structures (43, 48, 59). Although the cis-elements controlling
post-transcriptional regulation of gene expression were first
identified in yeast, similar mechanisms are now known in
mammalian cells. To date over two-thirds of identified mam-
malian genes that encode uORFs in their 5-UTRs are proto-
oncogenes (60–63). However, uORFs have also been identified
in a few genes with functions unrelated to cell growth control,
the S-adenosylmethionine decarboxylase gene (64, 65) and
Huntingtin gene (66). To these examples we now add the CFTR
gene. Further, the causative mutations in the inherited dis-
eases of familial melanoma (67, 68) and thrombocythemeia (69)
create or abolish uAUGs that result in dramatic alterations in
steady-state mRNA and protein levels.
It is estimated that less than 10% of eukaryotic mRNAs have
an uORF in their 5-UTR; however, very few have been inves-
tigated (48, 60). In general, uORFs lead to destabilization of the
mRNA of the main ORF, secondary to disruption of ribosome
scanning and reduced translation initiation at the main ORF
(43). All CFTR transcripts expressed in the heart have the
necessary 5-UTR elements, uORFs with adjacent stem-loop
structures, to allow post-transcriptional mechanisms to con-
tribute to the regulation of CFTR expression. We have shown
that the uORF, probably acting in concert with the adjacent
stem-loop, encoded in CFTRTRAD-139 transcripts functions to
reduce translation initiation efficiency at the downstream AUG
of the main CFTR ORF. In addition, the uORFs encoded in
exon 1C have a similar effect. With reduced translation re-
sulting in mRNA destabilization (43), it is probable that differ-
ential stability of CFTR transcripts in the heart may be a key
factor governing spatial, temporal, and pathological changes in
CFTR expression. Indeed, in cardiac tissues, different levels of
CFTR expression were measured over exons 1–2 compared
with exons 4–6 for all CFTR transcripts, suggesting that the
5-UTR elements involved in modulating translation efficiency
from the main AUG codon may also have a role in modulating
differential stability along the CFTR transcript. However, the
precise control of in vivo CFTR transcript stability remains
unclear.
The discovery that uORFs in CFTR 5-UTRs modulate CFTR
protein production has implications beyond the expression of
CFTR in the heart, as most mouse tissues express CFTR tran-
scripts that include an uORF (11). Also, the CFTR transcripts
expressed in human fetal lung, but not adult lung, include an
uORF (11), allowing the possibility that post-transcriptional
mechanisms may contribute to the large changes in CFTR
expression that occur during lung development. We have iden-
tified a conserved stable stem-loop structure in the 5-UTR of
traditional CFTR exon 1 that would be included in the majority
of CFTR transcripts expressed in all tissues. Similar stem-loop
structures have been shown to alter translation efficiency (49,
50). Whether 5-UTR encoded secondary structures lead to
widespread post-transcriptional regulation of CFTR expression
is under further investigation.
The cardiac potassium channels encoded by the HERG and
KvLQT1 genes are subject to alternative exon 1 usage, resulting
in distinct amino-terminal protein isoforms (70). Similarly, we
have shown that CFTR1C/1A transcripts contain an AUG codon
that is in-frame with the main CFTR ORF and directs transla-
tion of an unique CFTR protein isoform, bearing a 15-amino acid
truncation at the amino terminus. CFTR1B and CFTR1C tran-
scripts do not encode an in-frame AUG; however, translation may
initiate from downstream AUG codons in exons 3 and 4 (45). The
substantially higher levels of CFTR1C/1A transcripts suggest
that the majority of CFTR protein expressed in the heart is the
truncated amino-terminal isoform.
The regulation of CFTR protein trafficking and channel ac-
tivity has been shown to involve the amino terminus. Hydro-
philic residues of the H3 domain of syntaxin 1A physically
interact with a cytoplasmic amino-terminal helix of CFTR,
encoded in exons 2 and 3 (71, 72). Furthermore, an exon 1-en-
coded diphenylalanine motif (Phe-16/Phe-17) regulates CFTR
membrane trafficking (73). It has been suggested that loss of
CFTR exon 1 would remove both motifs (55). However, al-
though the diphenylalanine motif would be removed, the CFTR
domain that interacts with syntaxin 1A would remain as it is
encoded within exons 2 and 3. It was also suggested that the
CFTR domain that interacts with syntaxin 1A is hydrophobic
in nature and encoded at the exon 1/2 boundary (55). However,
hydrophobicity analysis demonstrates that the syntaxin 1A
interacting domain is in fact hydrophilic (Fig. 6B) (52). Our
analysis does indeed identify a CFTR amino-terminal hydro-
phobic region (residues 11–26) encoded at the exon 1/2 bound-
ary, first described by Davies (52). This hydrophobic region,
truncated by loss of exon 1, has a predicted helical structure
and may affect CFTR function or subcellular location by its
presence or absence. The putative helical structure of the
CFTR amino terminus (residues 11–26) is supported by the
recent identification, from the crystal structure (4.5 Å), of an
 helix of similar length and location within the amino termi-
nus (residues 10–21) of the ABC transporter homologue, MsbA,
from Escherichia coli (74).
We, and others, have established an absolute correlation
between CFTR mRNA expression, and the species-specific dis-
tribution of cardiac cAMP-activated chloride currents (14),
present in rabbits (15, 26), guinea pigs (20, 21), and monkeys
and humans (18). Antisense oligodeoxynucleotide inhibition
studies have confirmed CFTR as the molecular basis of the in
vivo cAMP-activated chloride current present in epithelial cells
and cardiomyocytes. Primary cultures of sweat duct epithelial
cells (75) and ventricular cardiomyocytes (25), as well as pan-
creatic duct (76) and colonic and tracheal epithelial cell lines
(77), were treated with antisense oligodeoxynucleotides that
bind up to 23 nucleotides surrounding the traditional CFTR
exon 1 translation initiation codon, present only in the
CFTRTRAD-74 and CFTRTRAD-139 transcripts. This resulted in
maximal inhibition (greater than 90%) of the endogenous
cAMP-activated chloride currents present in all cells of epithe-
lial origin. In contrast, there was only a partial inhibition
(
40%) of the endogenous cAMP-activated chloride currents in
ventricular cardiomyocytes, despite doubling the concentration
of antisense oligodeoxynucleotide. In all cases, sense oligode-
oxynucleotides had no effect on the cAMP-activated chloride
current and neither sense nor antisense oligodeoxynucleotides
had any effect on calcium-activated chloride conductance. Our
finding, that CFTRTRAD-139 mRNA accounts for only a small
proportion of the CFTR protein-coding transcripts present in
the heart, provides an explanation for the partial inhibition of
the cAMP-activated chloride current in ventricular myocytes
described by Hart et al. (25). The cardiac-specific CFTR1C/1A
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transcript we have identified will not bind the antisense oli-
godeoxynucleotides used by Hart et al. (25), and their findings
support our conclusion that CFTR1C/1A mRNA codes the
majority of CFTR protein and cAMP-activated chloride current
present in the heart. Further, it is specifically the differential
expression of the CFTR1C/1A transcript that is absolutely
correlated with differences in the whole cell current density of
cAMP-activated chloride currents in epicardial versus endocar-
dial ventricular myocytes (26), and the loss of cAMP-activated
chloride conductance in cardiac hypertrophy (78).
Overall, this work identifies multiple new levels at which
CFTR expression is regulated in vivo. This is the first study to
show the in vivo post-transcriptional regulation of CFTR ex-
pression through modulation of translation initiation efficiency
by 5-UTR encoded elements. Furthermore, this is probably a
widespread mechanism regulating CFTR expression. We are
also the first to show that, through alternative exon 1 usage, a
unique isoform of CFTR protein is generated and is likely to be
the major CFTR isoform present in the heart. This novel cur-
tailed form of CFTR protein, CFTR1C/1A, is missing function-
ally important amino-terminal motifs and is predicted to dis-
play unique subcellular localization and activity.
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Legend for Supplemental Figure. 
Cross-species analysis of CFTR in the human, rabbit and murine genomes. Dot plot analyses
showing identity between human, rabbit and murine (GenBank: AC000111 and AF162137)
genomic sequences, over regions spanning both the alternative and traditional CFTR exon 1
loci. The long closed black arrows represent a 5’ to 3’ direction. In (A), (C) and (E), the
alternatively spliced exon 1 sequences are coded: exon –1C, black; exon –1B, grey; exon
–1A, white. The traditional CFTR ATG codon is indicated in (B), (D) and (F), by a short
closed black arrow. Important structural elements are represented by open arrows, as follows:
GC rich region, no tail; Pu.Py stretch, circular tail; and an indel unit, diamond-shaped tail.
Horizontal bars represent a scale of 500 bp. 
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